Evidence map›Paper›PMID 40274522›Full record

ArticleChinese journal of traumatology = Zhonghua chuang shang za zhi2025

Dimethyloxalylglycine improves functional recovery through inhibiting cell apoptosis and enhancing blood-spinal cord barrier repair after spinal cord injury.

Wen Han, Chao-Chao Ding, Jie Wei, Dan-Dan Dai, Nan Wang, Jian-Min Ren, Hai-Lin Chen, Ling Xie

Abstract read
In one paragraph

Article in Chinese journal of traumatology = Zhonghua chuang shang za zhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wen HanDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China. Electronic address: 18840843748@163.com.
Chao-Chao DingDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China.
Jie WeiClinical Trial Institution, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China.
Dan-Dan DaiDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China.
Nan WangDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China.
Jian-Min RenDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China.
Hai-Lin ChenDepartment of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang province, China.
Ling XieMolecular Pharmacology Research Center, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang province, China. Electronic address: xieling0612@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe secondary damage of spinal cord injury (SCI) starts from the collapse of the blood spinal cord barrier (BSCB) to chronic and devastating neurological deficits. Thereby, the retention of the integrity and permeability of BSCB is well-recognized as one of the major therapies to promote functional recovery after SCI. Previous studies have demonstrated that activation of hypoxia inducible factor-1α (HIF-1α) provides anti-apoptosis and neuroprotection in SCI. Endogenous HIF-1α, rapidly degraded by prolylhydroxylase, is insufficient for promoting functional recovery. Dimethyloxalylglycine (DMOG), a highly selective inhibitor of prolylhydroxylase, has been reported to have a positive effect on axon regeneration. However, the roles and underlying mechanisms of DMOG in BSCB restoration remain unclear. Herein, we aim to investigate pathological changes of BSCB restoration in rats with SCI treated by DOMG and evaluate the therapeutic effects of DMOG.

methodsThe work was performed from 2022 to 2023. In this study, Allen's impact model and human umbilical vein endothelial cells were employed to explore the mechanism of DMOG. In the phenotypic validation experiment, the rats were randomly divided into 3 groups: sham group, SCI group, and SCI + DMOG group (10 rats for each). Histological analysis via Nissl staining, Basso-Beattie-Bresnahan scale, and footprint analysis was used to evaluate the functional recovery after SCI. Western blotting, TUNEL assay, and immunofluorescence staining were employed to exhibit levels of tight junction and adhesion junction of BSCB, HIF-1α, cell apoptosis, and endoplasmic reticulum (ER) stress. The one-way ANOVA test was used for statistical analysis. The difference was considered statistically significant at p < 0.05.

resultsIn this study, we observed the expression of HIF-1α reduced in the SCI model. DMOG treatment remarkably augmented HIF-1α level, alleviated endothelial cells apoptosis and disruption of BSCB, and enhanced functional recovery post-SCI. Besides, the administration of DMOG offset the activation of ER stress induced by SCI, but this phenomenon was blocked by tunicamycin (an ER stress activator). Finally, we disclosed that DMOG maintained the integrity and permeability of BSCB by inhibiting ER stress, and inhibition of HIF-1α erased the protection from DMOG.

conclusionsOur findings illustrate that the administration of DMOG alleviates the devastation of BSCB and HIF-1α-induced inhibition of ER stress.

Indexed as

Amino Acids, DicarboxylicApoptosisRecovery of FunctionSpinal CordSpinal Cord InjuriesAnimalsHypoxia-Inducible Factor 1, alpha SubunitMaleRatsRats, Sprague-DawleyAmino Acids, DicarboxylicHypoxia-Inducible Factor 1, alpha SubunitoxalylglycineBlood spinal cord barrierDimethyloxalylglycineEndoplasmic reticulum stressHypoxia inducible factor-1αSpinal cord injury

Identifiers

PMID40274522
PMCPMC12489486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.